Regenxbio Inc
(NAS:RGNX)
$
9.92
-0.09 (-0.9%)
Market Cap: 491.49 Mil
Enterprise Value: 320.09 Mil
PE Ratio: 0
PB Ratio: 1.63
GF Score: 65/100 Regenxbio Inc at Morgan Stanley Global Healthcare Conference (Virtual) Transcript
Sep 14, 2021 / 07:30PM GMT
Release Date Price:
$45.68
(+5.25%)
Vikram Purohit
Morgan Stanley, Research Division - Equity Analyst
Okay. Great. Thank you, everyone, for joining. My name is Vikram Purohit. I'm one of the biotech analysts with the Morgan Stanley research team. Very happy to have with me the team from REGENXBIO. Before we get into our fireside chat, just need to read a brief disclosure statement. So for important disclosures please see the Morgan Stanley research disclosure website at www.morganstanley.com/researchdisclosures. And if you have any questions, please reach out to your Morgan Stanley sales representative.
So with that, happy to introduce Ken Mills, CEO; and Steve Pakola, CMO from REGENXBIO. Ken, Steve, welcome.
Kenneth T. Mills
REGENXBIO Inc. - President, CEO & Director
Thanks, Vikram.
Questions & Answers
Vikram Purohit
Morgan Stanley, Research Division - Equity Analyst
And actually one more item before we get into our Q&A here.
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot